Reference : Methods of clinical and biological assessment of rheumatoid arthritis
Scientific journals : Article
Human health sciences : Rheumatology
http://hdl.handle.net/2268/94612
Methods of clinical and biological assessment of rheumatoid arthritis
English
Malaise, Michel mailto [Université de Liège - ULiège > Département des sciences cliniques > Rhumatologie >]
Franchimont, P. [ > > ]
1987
Scandinavian Journal of Rheumatology. Supplement
Steinviks Bokforlag
65
81-84
Yes (verified by ORBi)
International
0301-3847
Oslo
Norway
[en] Rheumatoid Arthritis
[en] Inflammation has long been recognised as notoriously difficult to measure both in
clinical practice and in the laboratory. Of all the cardinal features of
inflammation, pain relief is really what the patients want, and among disabled
persons, rheumatic patients are the only ones who must cope with chronic pain.
The rheumatologist, however, is also interested in other parameters that are
thought to reflect improvement of the inflammatory process. The methods used to
clinically assess rheumatoid arthritis (RA) should share the following four
parameters: validity, sensitivity, reliability and simplicity. Unfortunately, at
present, no single ideal method is capable of accurately reflecting disease
activity in RA. The measurement of pain relief by the visual analogue scale, the
determination of the Ritchie index and the duration of morning stiffness, plus
patient assessment of global response should be enough to detect clinical
activity of the drug in RA. If we are working with slow-acting drugs or so-called
disease modifying antirheumatic drugs (DMARDs), it should be appropriate to
include X-ray analysis and laboratory tests in the evaluation. A reduction in the
number of fresh erosions and/or the healing of present erosions can give reliable
information on the capacity of the drug to really modify the course of the
disease. At present, measurement of the erythrocyte sedimentation rate and of
acute phase serum proteins seems to offer the best available assessment during
early weeks of therapy. The other biological tests are of limited value in
reflecting or predicting a beneficial clinical response to DMARDs.
Researchers ; Professionals
http://hdl.handle.net/2268/94612

There is no file associated with this reference.

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.